British pharmaceutical company GSK has announced plans to invest $30 billion in the United States over the next five years. The investment, revealed on the first day of US President Donald Trump’s state visit to Britain, aims to enhance GSK’s research and development capabilities, as well as its production capacities in the US.
This significant investment comes as drugmakers face increasing pressure from President Trump to boost domestic production. The US president has imposed tariffs on various industries in an effort to reduce the country’s trade deficit, which he considers “unfair.” The pharmaceutical sector is among those affected, with the Trump administration urging companies to increase their production in the US.
GSK’s investment will include the construction of a $1.2 billion biologics factory in Pennsylvania, focused on developing treatments for respiratory and cancer diseases. The company will also develop artificial intelligence capabilities at its five US manufacturing sites. This move is expected to create hundreds of highly skilled jobs, adding to the 15,000 employees GSK already has in the US.
The announcement coincides with President Trump’s state visit to the UK, a rare privilege extended by King Charles III. The visit highlights the long-standing relationship between the two countries, particularly in the fields of science and healthcare innovation. As GSK’s chief, Emma Walmsley, noted, “This week’s state visit brings together two countries that have led the world in science and healthcare innovation.”
GSK’s commitment to investing in the US underscores the importance of the country’s pharmaceutical market and the company’s desire to strengthen its presence there. The investment is expected to bolster GSK’s position in the US market, while also contributing to the country’s goal of increasing domestic production. With this significant investment, GSK demonstrates its dedication to advancing healthcare innovation and creating new opportunities in the US.